Molecular characteristics and risk factors in endometrial cancer: what are the treatment and preventative strategies?
作者： Patricia E. Ellis , Sadaf Ghaem-Maghami
DOI: 10.1111/IGC.0B013E3181F1A400
关键词: Medicine 、 PTEN 、 Carcinogenesis 、 Clinical trial 、 Internal medicine 、 Disease 、 Pathogenesis 、 Endometrial cancer 、 PI3K/AKT/mTOR pathway 、 Oncology 、 Discovery and development of mTOR inhibitors
摘要: Objectives: The growing prevalence of endometrial cancer has made it necessary to characterize its molecular and clinical properties develop new strategies in treating this disease. A number genetic events have been observed cancers, which enabled us a better understanding the biology development For example, PTEN/AKT pathway downstream targets mTOR (mammalian target rapamycin) shown play an important role pathogenesis. Novel therapies, such as drugs that cellular pathways, for inhibitor deforolimus, analog rapamycin, developed used trials treat women with progressive cancer. This review outlines data on translational aspects cancers risk factors. Methods: literature search was performed using PubMed OvidSP entering words characteristics Results: An evidence-based summary factors obtained. Conclusions: Clear pathways involved tumorigenesis may allow identify at developing possibly intervene prevent development.
sci-hub.se 参考文章(116)
David Malkin, The role of p53 in human cancer. Journal of Neuro-oncology. ,vol. 51, pp. 231- 243 ,(2001) , 10.1023/A:1010636426860
K R Cho, T D Kessis, L Hedrick, R T Burks, Microsatellite instability in endometrial carcinoma. Oncogene. ,vol. 9, pp. 1163- 1166 ,(1994)
Andrzej Semczuk, Danuta Skomra, Marek Cybulski, Jerzy A. Jakowicki, Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochemical Journal. ,vol. 33, pp. 193- 200 ,(2001) , 10.1023/A:1017996506357
A Makedos, M Bobos, Ignace Vergote, A Papanikolaou, G Makedos, E Nenopoulou, I Amplianitis, I Kalogiannidis, Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. European Journal of Gynaecological Oncology. ,vol. 29, pp. 19- 25 ,(2008)
Lovell A. Jones, Jay George, Juan C. Felix, Adel El-Naggar, Bahman Saffari, Michael F. Press, Amplification and Overexpression of HER-2/neu (c-erbB2) in Endometrial Cancers: Correlation with Overall Survival Cancer Research. ,vol. 55, pp. 5693- 5698 ,(1995)
Osamu Tanizawa, Jerry M. Rice, Takayuki Enomoto, Masami Fujita, Taisei Nomura, Masaki Inoue, Ryuichi Nakajima, Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium Cancer Research. ,vol. 53, pp. 1883- 1888 ,(1993)
Jacqueline A. Lees, Elad Gil, Liang Ping Weng, Charis Eng, Charis Eng, Patricia L M Dahia, Wendy M. Smith, Ulrike Ziebold, PTEN Suppresses Breast Cancer Cell Growth by Phosphatase Activity-dependent G1 Arrest followed by Cell Death Cancer Research. ,vol. 59, pp. 5808- 5814 ,(1999)
Andrew Berchuck, John I. Risinger, Patrice Watson, Henry T. Lynch, Jeff Boyd, Matthew F. Kohler, Genetic instability of microsatellites in endometrial carcinoma. Cancer Research. ,vol. 53, pp. 5100- 5103 ,(1993)
Andrew Berchuck, John I. Risinger, J. Carl Barrett, A. Kate Hayes, PTEN/MMAC1 Mutations in Endometrial Cancers Cancer Research. ,vol. 57, pp. 4736- 4738 ,(1997)
B. Smith-Sørensen, Eivind Hovig, M. S. Greenblatt, Therese Sorlie, R. Montesano, M. Hollstein, C. C. Harris, K. Rice, R. Fuchs, T. Soussi, Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Research. ,vol. 22, pp. 3551- 3555 ,(1994)